Helminen Olli, Valo Johanna, Andersen Heidi, Söderström Johan, Sihvo Eero
Dept of Surgery, Central Finland Central Hospital, Jyväskylä, Finland.
Surgery Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
ERJ Open Res. 2021 Aug 16;7(3). doi: 10.1183/23120541.00110-2021. eCollection 2021 Jul.
With a population-based cohort in the video-assisted thoracoscopic surgery (VATS) era, we aimed to evaluate the value of the stair-climbing test (SCT) on short- and long-term outcomes of lung cancer surgery.
All patients operated due to primary lung cancer in Central Finland and Ostrobothnia from 2013 to June 2020 were included. For the analysis, clinical variables including the outcome of SCT and cause-specific mortality were available. Short- and long-term outcomes were compared between <11 m (n=66) and >12 m SCT (n=217) groups.
Patients with poor performance (<11 m) had more comorbidities and worse lung function but did not differ in tumour stage or treatment. No differences between groups were observed in major morbidity rate (10.6% 11.1%, p=0.918) or median hospital stay (5 (IQR 4-7) 4 (IQR 3-7), p=0.179). At 1-year, fewer patients were alive and living at home in the climbing <11 m group (81.3%) compared to the >12 m group (94.2%), p=0.002. No difference was observed in cancer-specific 5-year survival. Non-cancer-specific survival (62.9% 83.1%, p<0.001) and overall survival (49.9% 70.0%, p<0.001) were worse in the <11 m group. After adjustment for confounding factors, SCT remained as a significant predictor for non-cancer-specific (HR 4.28; 95% CI 2.10-8.73) and overall mortality (HR 2.38; 95% CI 1.43-3.98).
With SCT-based exercise testing, VATS can be performed safely, with a similar major morbidity rate in the poor performance group (<11 m) compared to >12 m group. Poor exercise performance increases non-cancer-specific mortality. Being a major predictor of survival, exercise capacity should be included in prognostic models.
在电视辅助胸腔镜手术(VATS)时代,我们基于人群队列研究,旨在评估爬楼梯试验(SCT)对肺癌手术短期和长期预后的价值。
纳入2013年至2020年6月在芬兰中部和博滕尼亚因原发性肺癌接受手术的所有患者。分析时可获取包括SCT结果和特定病因死亡率在内的临床变量。比较SCT<11米(n = 66)组和>12米(n = 217)组的短期和长期预后。
体能较差(<11米)的患者合并症更多,肺功能更差,但在肿瘤分期或治疗方面无差异。两组在主要发病率(10.6%对11.1%,p = 0.918)或中位住院时间(5(四分位间距4 - 7)对4(四分位间距3 - 7),p = 0.179)方面未观察到差异。1年时,与>12米组(94.2%)相比,爬楼梯<11米组存活且在家生活的患者较少(81.3%),p = 0.002。在癌症特异性5年生存率方面未观察到差异。<11米组的非癌症特异性生存率(62.9%对83.1%,p<0.001)和总生存率(49.9%对70.0%,p<0.001)更差。在调整混杂因素后,SCT仍然是非癌症特异性(风险比4.28;95%置信区间2.10 - 8.73)和总死亡率(风险比2.38;95%置信区间1.43 - 3.98)的显著预测因素。
基于SCT的运动测试表明,VATS可以安全进行,体能较差组(<11米)与>12米组的主要发病率相似。运动能力差会增加非癌症特异性死亡率。作为生存的主要预测因素,运动能力应纳入预后模型。